Anlon Healthcare IPO
Anlon Healthcare IPO — date, price band, lot size & details 2025
Anlon Healthcare listed on 3 Sep 2025 at ₹92, 1.1% above the ₹91 issue price.
Anlon Healthcare makes pharmaceutical intermediates and active pharmaceutical ingredients for medicines, nutraceuticals, personal care and animal health. Its profit after tax rose from Rs 5.82 crore in FY2023 to Rs 20.52 crore in FY2025.
Stock price
Anlon Healthcare is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 10 November.
- Open 26 Aug 2025
- Close 29 Aug 2025
- Allotment 01 Sep 2025
- Refund/credit 02 Sep 2025
- Listing 03 Sep 2025
Issue summary
The terms of the offer, as filed.
| IPO Dates | 26 to 29 Aug, 2025 |
|---|---|
| Price Band | ₹86 – ₹91 |
| Face Value | ₹10 |
| Lot Size | 164 Shares |
| Issue Size | ₹121.03 Cr |
| Sale Type | Fresh capital only |
| Listing On | BSE, NSE |
| Registrar | KFin Technologies Limited |
| Min Investment | ₹ 14,924 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 164 shares at the ₹91 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 164 | ₹14,924 |
| Retail (max) | 13 | 2,132 | ₹1,94,012 |
| S-HNI (min) | 14 | 2,296 | ₹2,08,936 |
| S-HNI (max) | 67 | 10,988 | ₹9,99,908 |
| B-HNI (min) | 68 | 11,152 | ₹10,14,832 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 5
- 01Profit after tax rose from Rs 5.82 crore in FY2023 to Rs 20.52 crore in FY2025.
- 02The PAT margin was 17.06% and the EBITDA margin was 26.88%.
- 03Net worth rose from Rs 7.37 crore on 31 March 2023 to Rs 80.42 crore on 31 March 2025.
- 04The whole Rs 121.03 crore issue was fresh capital.
- 05Return on equity was 40.45% and return on capital employed was 21.93%.
Risks · 7
- 01Total income fell from Rs 113.12 crore in FY2023 to Rs 66.69 crore in FY2024 before recovering to Rs 120.46 crore in FY2025, so income can swing.
- 02Return on equity of 40.45% is high partly because net worth was small, at Rs 21.03 crore on 31 March 2024.
- 03The P/E was 23.57 at the upper band of Rs 91, based on post-issue EPS of Rs 3.86.
- 04Total borrowing was Rs 58.35 crore on 31 March 2025, and debt to equity was 0.73.
- 05The company is small, with total assets of Rs 181.30 crore on 31 March 2025.
- 06Rs 43.15 crore of the proceeds was for working capital.
- 07Promoters held 70.26% before the issue and held 52.68% after it.
Three years of numbers
All figures in ₹ crore, as reported in the Anlon Healthcare offer document.
| Metric | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 181.30 | 128.00 | 111.55 |
| Total Income | 120.46 | 66.69 | 113.12 |
| Profit After Tax | 20.52 | 9.66 | 5.82 |
| EBITDA | 32.38 | 15.57 | 12.66 |
| NET Worth | 80.42 | 21.03 | 7.37 |
| Reserves and Surplus | 40.57 | 5.03 | -4.63 |
| Total Borrowing | 58.35 | 74.56 | 66.39 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Anlon Healthcare RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Anlon Healthcare IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Pre-Issue | Post-Issue |
|---|---|---|
| EPS (₹) | ₹5.15 | ₹3.86 |
| P/E Ratio (x) | 17.67 | 23.57 |
| Market Cap at Offer Price (₹ Cr) | ₹362.59 | ₹483.76 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹91 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
₹121.03 Cr of the issue is earmarked to named objects.
About the company
These products are raw materials for medicines such as tablets, capsules, ointments and syrups. They are also used in nutraceuticals, personal care and animal health products.
The products are manufactured to pharmacopeia standards including IP, BP, EP, JP and USP. The company also offers custom manufacturing of complex chemicals.
The IPO was a fresh issue of Rs 121.03 crore. Rs 43.15 crore was planned for working capital and Rs 30.72 crore for expansion.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Anlon Healthcare IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Interactive Financial Services Ltd.
5 issues handled (1 mainboard, 4 SME)Best listing: Aritas Vinyl (0.0%). Weakest: Shree Ram Twistex (-34.6%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Anlon Healthcare?
The current Grey Market Premium is ₹2, or 2% over the issue price.
What is the Anlon Healthcare IPO price band?
₹86 to ₹91, on a face value of ₹10.
When is the allotment?
The basis of allotment is 1 September 2025, with listing on 3 September 2025.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — KFin Technologies Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
